The Influence of Pluronic F68 and F127 Nanocarrier on Physicochemical Properties, In vitro Release, and Antiproliferative Activity of Thymoquinone Drug

Salwa Shaarani, Shahrul Sahul Hamid¹, Noor Haida Mohd Kaus

Department of Physical Chemistry, School of Chemical Science, Universiti Sains Malaysia, ¹Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200 Bertam, Kepala Batas, Pulau Pinang, Malaysia

ABSTRACT
Background: This study reports on hydrophobic drug thymoquinone (TQ), an active compound found in the volatile oil of Nigella sativa that exhibits anticancer activities. Nanof ormulation of this drug could potentially increase its bioavailability to specific target cells. Objective: The aim of this study was to formulate TQ into polymer micelle, Pluronic F127 (5.0 wt %) and Pluronic F68 (0.1 wt %), as a drug carrier to enhance its solubility and instability in aqueous media. Materials and Methods: Polymeric micelles encapsulated TQ were prepared by the microwave-assisted solvent evaporation technique. Fourier transform infrared spectroscopy and ultraviolet-visible spectrophotometer were utilized for qualitative confirmation of micelles encapsulation. The surface morphology and mean particle size of the prepared micelles were determined using transmission electron microscopy (TEM). Cytotoxicity effect was studied using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-[4-sulfophenyl]-2H-tetrazolium, inner salt (MTS) assay. Results: Dynamic laser light scattering (DLS) technique showed hydrodynamic size distribution of optimized micelles of 50 nm, which was in close agreement with the mean particle size obtained from TEM of about 51 nm. Drug release study showed the maximum percentage of TQ release at 61% after 72 h, while the entrapment efficiency of TQ obtained was 46% using PF127. The cytotoxic effect of PF127-encapsulated TQ was considerably higher compared to PF68-encapsulated TQ against MCF7 cells, as they exhibited IC₅₀ value of 8 µM and 18 µM, respectively. Conclusion: This study suggests higher molecular weight Pluronic polymer micelles (F127) with hydrophilic-hydrophobic segments which could be used as a suitable candidate for sustainable delivery of TQ. However, comprehensive studies should be carried out to establish the suitability of Pluronic F127 as a carrier for other drugs with similar challenges as TQ.

Key words: Cytotoxicity, MCF-7 cell line, pluronic F68, thymoquinone-nanoparticle

SUMMARY
There is a rising interest in integrating nanotechnology with medicine, creating a nanomedicine aiming for high efficiency and efficacy of disease diagnosis and treatment. In drug delivery, the term nanomedicine describes the nanometer-sized range (1–1000 nm) of a multi-component drug for disease treatments. As such, liposome-based nanoparticulate delivery vehicles have been approved by the Food and Drug Administration (FDA) for clinical applications. The main purpose of introducing nanoscale drug delivery is to improve the pharmacological and pharmacokinetic profiles of therapeutic molecules. Drug or therapeutic molecules can be either released through the cleavage of a covalent linkage between drug molecules and polymers (conjugation) or through the diffusion from a drug and polymer blended matrix (physical encapsulation). Polymers play an important role in the design of nanocarriers for therapeutic deliveries. In Asia, Nigella sativa seed oil has been used traditionally for its various medicinal benefits. One of its most potent compound which is thymoquinone has been intensively investigated for its anti-cancer effects in colorectal carcinoma, breast adenocarcinoma, osteosarcoma, ovarian carcinoma, myeloblastic leukemia, and pancreatic carcinoma. In addition, it is reported to show anti-inflammatory potential, anti-diabetic, antithrombotic effects, as well as the ability to alleviate respiratory diseases, rheumatoid arthritis, multiple sclerosis, and Parkinson’s disease. This study aims to formulate and characterize different pluronic-based thymoquinone nanocarrier and investigate its effect against breast cancer cells.

INTRODUCTION
There is an increasing interest in integrating nanotechnology with medicine, toward formulating nanomedicine aimed at high efficiency and efficacy of disease diagnosis and treatment.¹² Nanomedicine describes the nanometer-sized range (1–1000 nm) of a multi-component drug for disease treatments. The liposome-based nanoparticulate delivery system vehicles have been approved by the Food and Drug Administration for clinical application.¹² The main purpose of introducing nanoscale...
drug delivery is to improve the pharmacological and pharmacokinetic profiles of therapeutic molecules. Drug or therapeutic molecules can be either released through the cleavage of a covalent linkage between drug molecules and polymers (conjugation) or through the diffusion from a drug and polymer-blended matrix (physical encapsulation).

Polymers play an important role in the design of nanodrugs for therapeutic deliveries. There exists various polymeric nanomedicine for drug delivery systems such as polymer-protein conjugate,[13] polymer-small molecule conjugate,[14] dendrimer,[15] polymeric vesicle,[16] polymeric nanosphere,[17] and polymeric micelle.[18] Previous studies have reported on the formation of a poly (glycerol-succinic acid) dendrimer, in which building blocks such as glycerol and succinic acid are the natural metabolites.[19] This dendrimer exhibited a successful encapsulation of camptothecin (CPT), which is an anticancer drug with low water solubility.[20] Moreover, the dendrimer system has been reported to increase the aqueous solubility of CPT by approximately one order of magnitude. Furthermore, in vitro studies revealed that dendrimer enhances both the uptake and retention of these compounds within cancer cells.[21] Apart from that, polymer small molecule conjugate exhibited good track records since some preclinical success of these nanomedicine include N-(2-hydroxypropyl) methacrylamide copolymer, poly (glutamic acid) (PEG), (pGlu), dextran, and cyclodextrin-based polymer.[22] In addition, polymeric vesicle composed of polybutadiene is a well-known bilayer-forming polymer that can be subsequently cross-linked for enhanced vesicle stability.[23]

N. sativa seed oil is reported to have various medical benefits. It contains fixed oils, volatile oil, proteins, alkaloids, coumarins, saponins, minerals, carbohydrates, fiber, and water.[24] The plant has been reported to be commonly found in countries bordering the Mediterranean sea, Pakistan, and India.[25] It is reported that thymoquinone (TQ) inhibited the proliferation of several tumor cells such as colorectal carcinoma, breast adenocarcinoma, osteosarcoma, ovarian carcinoma, myeloblastic leukemia, pancreatic carcinoma, and brain tumor.[26,27] Moreover, TQ, the main active constituent of black seed oil, exhibits anti-inflammatory potential, antiabetic and antihistaminic effects, as well as the ability to alleviate respiratory diseases, rheumatoid arthritis, multiple sclerosis, and Parkinson's disease.[28] Besides that, the antioxidant effect possessed by TQ has protected several organs against oxidative damage induced by free radical-generating agents such as doxorubicin-induced cardiotoxicity. Singh et al. reported that TQ was employed in biodegradable nanoparticulate formulation based on poly (lactide-co-glycolide) (PLGA) and the stabilizer polyethylene glycol (PEG)-5000. The other form includes TQ-encapsulated nanocarrier for nose-to-brain targeting.

In vitro release, and antiproliferative effect.

**MATERIALS AND METHODS**

**Reagents**

TQ (Sigma Aldrich, 99% purity), Pluronic F127 (molecular weight of 12,500 Da), and Pluronic F68 (molecular weight of 8500 Da) were purchased from Sigma-Aldrich. Acetonitrile is of analytical grade, and it was purchased from Fisher scientific. Mili-Q grade water was used for the preparation of all solutions. The established human breast cancer cell line MCF-7 was obtained from American Type Culture Collection. Phosphate-buffered solution was purchased from Fisher scientific and it was sterilized before use.

**Preparation of PF127- and PF68-encapsulated thymoquinone in aqueous phase**

Initial step involved preparation of stock solution by dissolving in dimethyl sulfoxide. Followed by preparation of different concentrations comprising 0.3, 0.7, and 1.1 mM and dissolved in 1 ml acetonitrile. The emulsion formed was then stirred for 20 min. The PF127 and PF68 were dissolved in Milli Q and then 20 ml of PF127 or PF68 was added. The colloidal suspension was then left to stir for overnight. It was then placed in a microwave (700 Watt) to evaporate the organic solvent. The study also utilized copolymer PF68 to encapsulate TQ to compare the differences with PF127. Finally, the suspension was filtered with a 0.22 µm (biofilm) syringe filter to remove contaminants.

**Fourier transform infrared spectroscopic study**

The PF127- and PF68-encapsulated TQ were examined by Attenuated Total Reflectance-Infrared (ATR-IR) spectrometer Frontier Perkin Elmer to confirm the success of encapsulation. The range of the scan covered from 4000 to 650 cm⁻¹.

**Qualitative ultraviolet-visible spectrophotometric analysis**

The synthesis of PF127 and PF68 encapsulated TQ was monitored by ultraviolet-visible (UV-VIS) spectrophotometer Shimadzu (UV 2600) to determine the maximum wavelength (λmax) of TQ, and the samples were scanned between 200 and 400 nm.

**In vitro drug release from pluronic formulation**

The formulation of TQ loaded in two different systems, each PF127 and PF68, respectively, were placed in a dialysis bag (10 kDa MWCO, Thermo Scientific Inc., Rockford, IL, USA), suspended in 200 mL phosphate-buffered saline (PBS) at a pH of 7.4. To mimic the physiological condition of body systems, the samples were monitored at a constant temperature (37°C) while continuously stirring at 200 rpm. After each time interval, 3 mL of the samples was withdrawn and replaced with the same amount of fresh release medium. For each group, three samples were taken (n = 3) for measurements. The amount of TQ released was determined by UV-VIS spectrophotometer.
Determination of entrapment efficiency

Percentage of drug entrapped was evaluated in terms of the entrapment efficiency (% EE) with respect to the overall drug loaded in the formulation.

To determine the entrapment efficiency (% EE) of PF127- and PF68-encapsulated TQ, the samples were first sonicated for 3 min and vortexed for a few seconds. Drugs were then separated by ultracentrifugation at 14,000 rpm at room temperature for 30 min.

The resulting supernatant was collected and quantified spectrophotometrically (UV-VIS spectrophotometer Shimadzu) at 257 nm. The amount of drug entrapped (% EE) was calculated by the following equation:

\[
\text{Percentage of EE} = \left(\frac{\text{Amount of TQ in NPs}}{\text{Total amount of TQ}}\right) \times 100\%
\]

EE-entrainment efficiency

NPs-nanoparticle

Cell culture and proliferation assay

The cells were cultured in RPMI-1640 (Gibco) media supplemented with 10% fetal bovine serum (JR Scientific) and antibiotics (10,000 Units/ml penicillin and 10,000 µg/ml streptomycin) (Gibco) under a humidified atmosphere containing 5% CO₂. Each 96-well plate was seeded with a density of 3000 cells/well in 200 µl of fresh culture medium and incubated at 37°C under CO₂ atmospheric condition. The cells were then left to adhere to the plate before treatment with nanoparticles the concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 µM. Free TQ (without micelles), PF127-encapsulated TQ, and PF68-encapsulated TQ were treated for 24, 48, and 72 h, respectively. The medium was removed, and 100 µl of fresh medium mixed with 20 µl of CellTiter 96 AQ nonradioactive cell proliferation assay was pipetted into each well. This reagent contained 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate to quantify the number of viable cells in proliferation. Each well plate was incubated for 3 h at 37°C in a humidified condition of 5% CO₂ atmosphere.

Absorbance of each concentration was read at 490 nm using an ELISA microplate reader. The untreated cells were used as a negative control. Each concentration was repeated in quadruplicates. The amount of formazan product as measured at 490 nm absorbance is directly relative to the number of surviving cells in the samples. Percentage of cell viability was calculated as follows:

\[
\text{Viability} (%) = \left(\frac{A_{\text{sample}}}{A_{\text{control}}}\right) \times 100
\]

Statistical analysis

The experiments were done in quadruplicates, and the values were compared using one-way ANOVA performed in Statistical Package for the Social Sciences (SPSS) software IBM (Armonk, New York, USA). \( P < 0.05 \) was considered statistically significant. All quantitative data were expressed as mean ± standard deviation.

RESULTS

Attenuated Total Reflectance (ATR-IR)

The results of ATR-IR were depicted in Figure 1. Analysis indicated the presence of depression at similar wavenumber for raw TQ and TQ-nanoparticle in both pluronic PF68 and PF127.

Ultraviolet-visible spectrophotometer

Analysis of nanoparticles using UV/VIS spectrophotometer showed peak absorbance at 257 nm with both pluronic and TQ acetonitrile as shown in Figures 2 and 3.

Entrapment efficiency

Percentage of weight per volume and entrapment efficiency measured in PF68 TQ-nanoparticle and PF127 TQ-nanoparticle were shown in Table 1. For PF68 TQ-nanoparticles, entrapment efficiency was highest with 0.1% weight per volume. It was noted that entrapment efficiency increased with increase in concentration. However, 5% weight per volume was selected.

Transmission electron microscopy with thymoquinone loaded in 5% PF127

The TQ-nanoparticles were observed under transmission electron microscopy (TEM) to measure its size and morphology. Results provided in Figure 4 showed the difference in the sizes between 0.3 mM and 1.1 mM TQ. Regular-shaped particles formed with 1.1 mM TQ with an average size of 51 nm.

Figure 1: ATR-IR spectra of (a) raw thymoquinone, (b) thymoquinone in acetonitrile, (c) raw pluronic, (d) sample of lyophilized 5% PF127 encapsulated thymoquinone and (e) sample of lyophilized 0.1% PF68 encapsulated thymoquinone

Figure 2: Ultraviolet-visible spectrum showing maximum wavelength at 257 nm for control thymoquinone in acetonitrile
Transmission electron microscopy with thymoquinone loaded in 0.1% PF68

The TQ-nanoparticles were observed under TEM to measure its size and morphology. Results shown in Figure 5 indicate the difference in the sizes between 0.3 mM and 1.1 mM TQ. The 0.3 mM TQ produced particles with an average of 200 nm, but smaller particles were formed with 1.1 mM TQ with an average size of 40 nm.

Transmission Electron Microscopy with PF127

Based on an earlier finding, 1.8 mM was selected to formulate PF127 TQ-nanoparticles and size was determined using TEM as shown in Figure 6a. Hydrodynamic size showed an average of 50.75 nm and 7.53 nm (Figure 6b).

Transmission electron microscopy with PF68

Further investigation with 1.1 mM PF68 TQ-nanoparticles showed sizes between 10 and 70 nm as shown in Figure 7a. However, hydrodynamic size showed peak at size of 41 nm (Figure 7b).

Determination of zeta potential

The surface properties of nanoparticle drugs play a crucial factor because it affects the interaction with the local environment, which depends on a combination of size and surface properties. Furthermore, the surface properties will determine their solubility, stability, and clearance [41]. It was noted that the 0.3 mM polymeric micelles of PF127-encapsulated TQ exhibited the surface charge of $-13.1 \pm 1.12$ mV, meanwhile the PF68-encapsulated TQ is $-11.7 \pm 1.96$ mV. Surface charge of PF127/ TQ and PF68/TQ formulated at a concentration of 0.7 mM exhibited zeta value of $-4.29 \pm 0.79$ mV and $-5.94 \pm 5.55$ mV, respectively. At highest molar concentration of 1.1 mM of both formulations, the zeta potential obtained increased to $-15.3 \pm 0.36$ mV and $-16.1 \pm 2.66$ mV, respectively.

Drug release study

In the present study, maximum percentage of TQ released from the control system was 51%, meanwhile the release from encapsulated PF127 micelles was 62% in 48 h. The 1st h exhibited 44% of TQ released from control system [Figure 8a] whereas only 25% of TQ was released from the micelles system [Figure 8b]. The results revealed that TQ released from the polymeric micelle follows a slow and constant release rate compared to free TQ. It was noted that after 10 h the percentage of drug release was in a plateau.

Further experiment was carried out with 1.8 mM TQ-loaded 0.1% PF68, and the percentage of the drug release was 52% and similar to control [Figure 9a and b]. This was achieved within <10 h. It was also noted that further incubation did not show any increase in drug release. The 0.1% PF68 micelles showed complete drug release within 25 h.

Effects of pH on the stability and solubility of thymoquinone-encapsulated PF127

The stability and solubility of TQ were evaluated by employing different pH values of gastrointestinal tract (pH 1, 5, and 7) in PBSs as well as in water dispersion. Tables 2 and 3 summarize the results of stability and solubility obtained from PF127- and PF68-encapsulated TQ, respectively. The solubility behavior for 3 consecutive days in various pH values showed almost similar solubility range from 51.40 to 72.67 $\mu$g/mL.

Influence of storage time on the stability of PF127-encapsulated thymoquinone

The stability of formulated PF127 nanodrug is shown in Table 4. There were no significant changes in the physicochemical stability over storage period of 7, 14, and 21 days at room temperature.

Dose- and time-dependent effects using cell viability assay

In this study, the cytotoxic effects of TQ NPs and TQ free were demonstrated on MCF-7 breast cancer cell lines based on time- and dose-dependent manner by using MTS assay. From the results in Figure 10, TQ NPs suppressed the growth of breast cancer cell lines.

Table 1: Percentage for the amount of drug entrapped in the micelles core of each 1.1 mM of (a) PF68 encapsulated TQ and (b) PF127 encapsulated TQ. Data is presented as mean±standard deviation (n=3).

| PF68 encapsulated TQ NPs | PF127 encapsulated TQ NPs |
|--------------------------|---------------------------|
| Percentage of weight per volume (%) | Entrapment efficiency (%) | Percentage of weight per volume (%) | Entrapment efficiency (%) |
| 0.1                      | 42.1±1.21                 | 5.0                        | 46.6±1.03                 |
| 0.5                      | 35.4±1.09                 | 7.5                        | 49.2±0.85                 |
| 1                        | 33.9±2.75                 | 10                         | 60.1±0.55                 |

| PF68 encapsulated TQ NPs | PF127 encapsulated TQ NPs |
|--------------------------|---------------------------|
| Percentage of weight per volume (%) | Entrapment efficiency (%) | Percentage of weight per volume (%) | Entrapment efficiency (%) |
| 0.1                      | 42.1±1.21                 | 5.0                        | 46.6±1.03                 |
| 0.5                      | 35.4±1.09                 | 7.5                        | 49.2±0.85                 |
| 1                        | 33.9±2.75                 | 10                         | 60.1±0.55                 |

Figure 3: Ultraviolet-visible spectrum showing maximum wavelength at 257 nm for 1.8 mM (a) PF68 encapsulated thymoquinone (b) PF127 encapsulated thymoquinone

Figure 4: Transmission electron microscopy images of PF127/thymoquinone at various concentration of (a) 0.3 mM, (b) 0.7 mM, and (c) 1.1 mM

Figure 5: Transmission electron microscopy with thymoquinone loaded in 0.1% PF68

The TQ-nanoparticles were observed under TEM to measure its size and morphology. Results shown in Figure 5 indicate the difference in the sizes between 0.3 mM and 1.1 mM TQ. The 0.3 mM TQ produced particles with an average of 200 nm, but smaller particles were formed with 1.1 mM TQ with an average size of 40 nm.

Figure 6a: Hydrodynamic size showed an average of 50.75 nm and 7.53 nm [Figure 6b].

Figure 7a: Hydrodynamic size showed peak at size of 41 nm [Figure 7b].
Figure 5: Transmission electron microscopy images of PF68/thymoquinone at various concentration of (a) 0.3 mM, (b) 0.7 mM, and (c) 1.1 mM.

Figure 6: (a) Particle size distribution for polymer micelles 1.8 mm thymoquinone loaded 5% PF127 (70.93 ± 17.55) nm (b) average hydrodynamic size for polymer micelles 1.8 mm thymoquinone loaded 5% PF127.

Figure 7: (a) Particle size distribution for 1.8 mM thymoquinone loaded 0.1% PF68 (37.74 ± 12.94) nm (b) Average hydrodynamic size for 1.8 mM thymoquinone loaded 0.1% PF68.

Table 2: pH effects towards the stability and solubility of PF127/TQ

| pH     | Particle size (nm) | Zeta potential (mV) | Solubility(µg/mL) | 24 hours | 48 hours | 72 hours |
|--------|--------------------|---------------------|-------------------|----------|----------|----------|
| 1(PBS) | 46                 | 0.04±0.75           | 85.05±0.02        | 95.94±0.01 | 81.66±0.02 |          |
| 5(PBS) | 30                 | -6.76±1.03          | 98.98±0.01        | 98.99±0.01 | 91.54±0.01 |          |
| 7(PBS) | 30                 | -6.73±0.58          | 103.24±0.03       | 80.56±0.03 | 92.08±0.02 |          |
| Water  | 50                 | -15.3±0.36          | 67.92±0.06        | 41.49±0.01 | 33.26±0.00 |          |

with IC_{50} values for TQ-loaded PF127 NPs after 24 h, 48 h, and 72 h determined at 20, 7, and 8 µM, respectively. Meanwhile, TQ-loaded PF68 NPs IC_{50} values after 24 h, 48 h, and 72 h were 30, 12, and 18 µM, respectively [Figure 11].
Antiproliferative effects of TQ free (without micelles) and the control were studied through morphological changes as shown in Figure 12. Images showed reduction in cell number and size over time when treated with PF68 and PF127 compared to the control pluronic.

**DISCUSSION**

**Optimization of thymoquinone concentrations using Pluronic PF127 and PF68**

This analysis was done to select the optimal concentration for TQ encapsulation with Pluronic P127 and P68. Three different concentrations of TQ were studied at 0.3 mM, 0.7 mM, and 1.1 mM in both Pluronic PF68 and PF127 formulations. At 0.3 mM PF127/TQ, the morphology was found to form a network of bridging interaction within the excess hydrophilic tail of polymeric micelles presence [Figure 1a]. At 0.7 mM, the morphology of the encapsulated nanodrug exhibited spherical shape with small aggregation of chain network [Figure 1b]. This shows better encapsulation of the polymer micelle F127 with good distribution and low aggregation. It is interesting to note that, at 1.1 mM, TQ-encapsulated PF127 showed a good spherical morphology and evenly distributed particles in the system [Figure 1c]. This shows better encapsulation of the polymer micelle F127 with good distribution and low aggregation. It is interesting to note that, at 1.1 mM, TQ-encapsulated PF127 showed a good spherical morphology and evenly distributed particles in the system [Figure 1c]. Next, the TQ formulation system using lower molecular weight polymer micelle of PF68 was studied. At lower concentration of 0.3 mM, TQ showed that there was no nanodrug formation based on the TEM images [Figure 2a]. This could be due to the encapsulation process using low-molecular weight of polymeric micelles (PF68) with lower chain in core and corona which was not optimal for the entrapment of TQ. However, further increase in the concentration of TQ to 0.7 mM showed rough and indistinct shape of nanodrugs [Figure 5]. Increase in concentration up to 1.1 mM demonstrated that the TQ particles were encapsulated in more distinct shapes among the neighboring micelles as shown in Figure 5. Based on these findings, it was noted that the formulation of TQ was dependent on drug concentration which affected the morphology and particle distribution of the encapsulated drug. It was noted that the 1.1 mM TQ to be optimal for encapsulation in both PF127 and PF68. It conclusively showed better encapsulation with discrete and homogeneous particles. Hence, this concentration was selected for further characterizations of physicochemical, in vitro release, and toxicity studies. Study on pluronic-based nanodrug stability based on particle size diameter, hydrodynamic size, and zeta potential. Particle size was measured using dynamic light scattering (DLS), and peak was noted with 1.1 mM PF127/TQ at 50.75 nm and another peak with smaller size of 7.65 nm. This represents excess free micelles in the dispersion. Analysis on similar concentration of TQ encapsulated with lower molecular weight of F68 showed peak at 41 nm with two distinct peaks at 23 nm and 68 nm. The three different peaks appeared due to the polydisperse nature of TQ nanodrug. It was noted that the particle size distribution of PF127/TQ had an average mean size of 37.74 ± 12.94 nm. Furthermore, our findings showed that lower absolute value of zeta potential was influenced by the nature of nonionic surfactants of Pluronic PF127 and PF68. The nanodrug particles were sterically stabilized by both polymer micelles, and the surface charges that are slightly negative is reported to assist in the cellular uptake and will minimize the nonspecific interaction toward cell membrane. As the value of surface charge increases (either negative or positive), macrophage scavenging will be increased and lead to greater clearance.

**Table 3: pH effects towards the stability and solubility of PF68/TQ**

| pH  | Particle size (nm) | Zeta potential (mV) | Solubility (µg/mL) |
|-----|--------------------|---------------------|--------------------|
| 1 (PBS) | 41                 | 16.1±1.25           | 61.81±0.01                     |
| 5 (PBS) | 53                 | -14.6±0.21          | 69.14±0.00                     |
| 7 (PBS) | 59                 | -10.4±0.95          | 72.67±0.01                     |
| water | 41                 | -16.1±2.66          | 7.21±0.00                      |

**Figure 8:** Percentage drug release for control (a) thymoquinone in CH3CN and (b) PF127/thymoquinone micelles in 48 h

**Figure 9:** Percentage drug release for (a) thymoquinone loaded in 0.1% PF68 and (b) control thymoquinone in CH3CN for 50 h, respectively
by the reticuloendothelial system, hence reduces the diffusion of nanodrugs to the target cells. [24]

**Effects of pH on the stability and solubility of thymoquinone-encapsulated PF127**

The stability and solubility analyses showed that all encapsulated drugs sustained minimal degradation in phosphate buffer saline of pH 1 as particle size obtained was 46 nm. The size obtained is almost similar as in aqueous solutions. It can be concluded that the formulation is stable at extreme acidic condition. The solubility at 24 h, 48 h, and 72 h depicted a comparatively similar solubility ranging from 81.66 to 103.24 µg/mL for all examined pH values. However, specific solubility value is yet to be determined for TQ in these solutions due to the physical and chemical properties of the drug that may interfere with the soluble drug fraction. [25] Therefore, further reports are required to explore the possible degradation pathways and the resultant products to have a better comprehensive study on the noted fluctuations in the solubility profile.

Findings on PF68-encapsulated TQ showed solubility characteristics for 3 consecutive days in various pH values that were almost similar with solubility range between 51.40 and 72.67 µg/mL. The fluctuations in characteristics might be due to volatile oil of TQ. [26] Nevertheless, the results suggested that TQ showed a good water solubility when incorporated in Pluronic aqueous solutions. It can be noted that utilizing lower molecular weight of Pluronic F68 with shorter chain of core and corona resulted in instability in the surface charge of the nanodispersion. At lower pH, zeta potential observed to be positively charged (16.1 ± 1.25 mV), and the values were decreasing as the pH of PBS increases.

Therefore, it can be concluded that the formulation of PF127/TQ nanodispersion exhibited better physicochemical properties compared to PF68/TQ.
to the formulation of PF68/TQ. Figures 4 and 5 shows the correlation between the particle size and zeta values of PF127/TQ observed in different pH values. From the plot, PF127/TQ exhibited a low-negative zeta potential value and smaller particles size observed as the pH of the formulation in the buffer system increases. Previous works reviewed that the low-negative zeta potential would be useful in cellular uptake of TQ nanoparticles since it may assist in the reduction of electrostatic barrier which increases the chances of cellular uptake. The buffer systems were used to mimic the physiological condition of gastrointestinal tract, and it is interesting to note that the results obtained confirmed that this nanodrug formulation was highly stable and soluble regardless of any pH dispersion, hence makes it useful in predicting the drug absorption throughout the gastrointestinal tract.

**Influence of storage time on the stability of thymoquinone-encapsulated PF127**

This study indicated there were no significant changes on the physicochemical stability observed over a storage period of 7, 14, and 21 days at room temperature. The slight difference of zeta potential over storage time concluded that colloidal stability of nanodispersion was achieved due to steric repulsion that exists between polymers added into the system and was adsorbed onto the particle surface and thus prevent them from flocculating. If enough polymer adsorbs onto the particles, optimum thickness layer is achieved to keep particles separated by steric repulsions, and at this state, van der Waals interactions are too weak to adhere the particles together.

The particle size of the nanodrug which maintained at 51 nm confirms that this formulation was stable up to 14 days and it is suitable for long-term administration. However, particle size was reduced to 21 nm after 21 days and might be due to the evaporation of TQ drug upon time.

**In vitro drug release**

The maximum percentage of TQ released from the control system was 51%, whereas release from encapsulated PF127 micelles was 62% in 48 h. The 1st h exhibited 44% of TQ release from control system, however, only 25% of TQ was released from the micelles system. The results revealed that TQ released from the polymeric micelle follow a slow and constant release rate compared to free TQ. Basically, in a micelle, there exists three different types of locations of drug, namely, the core, core–corona interface, and at the corona. In the core sections, the drug entrapped has the longest diffusional path relative to that of the drugs located at core–corona interface or known as hydrophobic–hydrophilic interface or the corona. The burst release is triggered by the drug located at the core–corona interface or corona. In a control TQ system, a burst release pattern was based on the fact on the solubility of the drug and the partition coefficients which lead to rapid release due to thermodynamic imbalance. On the contrary, Figure 8b depicted a slow TQ release profile which is due to the localization of drug at the core site after the encapsulation with PF127.

For drug release pattern of PF68-encapsulated TQ relative to the TQ in control CH3CN, findings at 1st h showed similar percentage of TQ release with 44%. The total maximum TQ release throughout the study for control TQ was 51%; however, for PF68 nanodrug formulation, it exhibited a gradual decrease after 3 h, and finally, there was no TQ release after 24 h. The results suggested that PF68 no longer can encapsulate TQ upon exposure to aqueous solution at longer time. This initial burst release pattern might be due to some amount of the drug was absorbed on the surface or loosely bound to the inner polymer core and was lost during the initial preparation stage. Apart from that, TQ is a volatile oil; hence, it has been evaporated toward the end of the study.

**Entrapment efficiency**

The optimum entrapment efficiency for 5 wt% PF127- and 0.1 wt% PF68-encapsulated TQ was 46.6% and 42.1%, respectively. Theoretically, increase in the percentage of Pluronic F127 to more than 10% w/w would result in the formation of gel due to micellar enlargements. It is reported to be more entangled at higher concentration. Furthermore, the number and size of micelles within the gel structure increase and cause a decrease in the number and dimension of water channels, consequently leading to higher viscosity and lower drug release rate. Therefore, even though PF127-encapsulated TQ showed highest percentage of TQ entrapped at 10% w/v of PF127, yet 5% w/v of PF127 was selected in this study.

**CONCLUSION**

This study reports the differences in the characteristic of TQ-nanodrug formulated with pluronic F68 and F127. Encapsulation of TQ employing different molecular weights of amphiphilic triblock copolymer Pluronic F127 and Pluronic F68 in aqueous nanodispersion was performed by using emulsion-solvent evaporation technique. Characterization was done with ATR-IR, UV/VIS, TEM, and DLS analysis. The triblock copolymer assembled into spherically shaped structure with PEO hydrophilic chain at the hydrated segments and trapped TQ drug at the inner core of hydrophobic PPO in aqueous phase with smaller dimension of particle size. PF127/TQ and PF68/TQ were sterically stabilized with low-negative zeta potential values. PF127/TQ nanodispersion showed enhanced in solubility and stability regardless of any pH as to mimic the condition present in human gastrointestinal tract. A hydrophobic drug TQ was efficiently encapsulated in the core of Pluronic micelles. Higher entrapment efficiency was obtained from PF127-encapsulated TQ and more sustained release of drug relative to that of PF68-encapsulated TQ in aqueous nanodispersion. As compared to the PF68 nanodispersion, PF127 nanodispersion system exhibited higher toxicity toward MCF-7 cell lines. Stability of PF127 nanodispersion system was maintained up until 14 days duration of storage. Thus, different molecular weights and number of hydrophilic–hydrophobic segments of Pluronic showed significant results on the physicochemical properties, in vitro release, and antiproliferative effect of TQ drug toward MCF-7 cancer cell. It can be concluded that higher molecular weight with longer hydrophilic–hydrophobic segments of Pluronic polymer micelles (F127) could be used as a suitable candidate for the sustained delivery of drugs.

**Financial support and sponsorship**

This study was funded by Universiti Sains Malaysia RUI grant 1001/ CPPPT/812138.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Arulkumar S, Sabesan M. Rapid preparation process of antiparkinsonian drug *Mucuna pruriens* silver nanoparticle by bioreduction and their characterization. Pharmacognosy Res 2010;2:233-6.
2. Barenholz Y. Liposome application: Problems and prospects. Curr Opin Colloid Interface Sci 2001;6:66-77.
3. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8.
4. Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther 2007;6:2928-37.
5. Gopin A, Ebner S, Attali B, Shabat D. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly (ethylene glycol) via click chemistry. Bioconjug Chem 2006;17:1432-40.
6. Lee JS, Jeon J. Polymersomes for drug delivery: Design, formation and characterization. J Control Release 2012;161:473-83.

7. Gref R, Minamitake Y, Peracchia MT, Trubetskov V, Torchilin V. Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-3.

8. Jhaiveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol 2014;5:77.

9. Degoricija I, Bansal PN, Sontjens SH, Joshi NS, Takahashi M, Snyder B, et al. Hydrogels for osteochondral repair based on photocrosslinkable carbamate dendrimers. Biomacromolecules 2008;9:2863-72.

10. Kong X, Yu K, Yu M, Feng Y, Wang J, Li M, et al. A novel multifunctional poly (amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin. Int J Pharm 2014;465:378-87.

11. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, et al. Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 2006;66:11913-21.

12. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006;57:654-62.

13. Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006;8:323-41.

14. Muhammad A, Randhawa S, Al-Ghamdi M. A review of the pharmaco-therapeutic effects of Nigella sativa. J Med Food 2002;41:40-50.

15. El-Dakhakhny M, Barakat M, El-Halim MA, Aly SM. Effects of Nigella sativa oil on gastric secretion and ethanol induced ulcer in rats. J Ethnopharmacol 2000;72:299-304.

16. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol 2010;79:1640-7.

17. Ashour AE, Ahmed AF, Kumar A, Zoheir KM, Aboul-Soud MA, Ahmad SF, et al. Thymoquinone inhibits growth of human medulloblastoma cells by inducing oxidative stress and caspase-dependent apoptosis while suppressing NFκB signaling and IL-8 expression. Mol Cell Biochem 2016;418:141-55.

18. Schneider-Stock R, Fakhoury IH, Zaki AM, Al-Bawab A. Thymoquinone-Nanocarrier on Breast Cancer Cells. A novel multifunctional nanocarrier formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces 2013;102:822-32.

19. Shah M, Choi MH, Ullah N, Kim MO, Yoon SC. Synthesis and characterization of PHV-block-mPEG diblock copolymer and its formation of amphiphilic nanoparticles for drug delivery. J Nanosci Nanotechnol 2011;11:5702-10.

20. Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: A pharmacoscintigraphic study. Int J Nanomedicine 2012;7:5705-18.

21. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.

22. Salmani JM, Asghar S, Lv H, Zhou J. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules 2014;19:5925-39.

23. Shah M, Choi MH, Ullah N, Kim MO, Yoon SC. Synthesis and characterization of PHV-block-mPEG diblock copolymer and its formation of amphiphilic nanoparticles for drug delivery. J Nanosci Nanotechnol 2011;11:5702-10.

24. Shamsi JM, Asghar S, Lv H, Zhou J. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules 2014;19:5925-39.

25. Gali-Muhtasib H, Roesaner A, Schneider-Stock R. Thymoquinone: A promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 2006;38:1249-53.

26. Bhattacharya S, Ahir M, Patra P, Mukherjee S, Ghosh S, Mazumdar M, et al. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials 2015;51:91-107.

27. Zeta Potential: An Introduction in 30 Minutes. Available from: http://www.malvern.com/en/support/resource-center/technical-notes/ TN011042ZetaPotentialIntroduction.aspx. [Last accessed on 2005 Apr 07].

28. Gill KK, Kaddoumi A, Nazal S. PEG-lipid micelles as drug carriers: Physicochemical attributes, formulation principles and biological implication. J Drug Target 2015;23:222-31.

29. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001;73:121-36.

30. El-Kamal AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 2002;241:47-55.

ABOUT AUTHOR

Dr. Noor Haida Mohd Kauss is a senior lecturer at School of Chemical Sciences, Universiti Sains Malaysia.